An observational study in Metastatic Renal Cell Carcinoma, sponsored by First Affiliated Hospital of Fujian Medical University. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.
Sponsored by First Affiliated Hospital of Fujian Medical University · Observational
This single-center retrospective observational study evaluates whether quantitative imaging features from pretreatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) can help predict response to first-line tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI) therapy in patients with metastatic renal cell carcinoma.
The study reviews existing medical records and imaging data from 228 patients treated at the First Affiliated Hospital of Fujian Medical University between January 2019 and December 2025. Treatment was selected as part of routine clinical care and was not assigned by the study. Imaging features are extracted separately from the primary kidney tumor and metastatic lesions and are then combined to develop a patient-level multi-lesion radiomics model.
Treatment response is assessed according to Response Evaluation Criteria in Solid Tumors version 1.1 approximately 12 weeks after treatment initiation. Complete response or partial response is classified as response, whereas stable disease or progressive disease is classified as non-response. The study compares imaging-based, clinical, and combined prediction models and also evaluates their association with progression-free survival.
Patients with metastatic renal cell carcinoma may have different responses to first-line treatment combining a tyrosine kinase inhibitor with an immune checkpoint inhibitor. Differences may also occur among the primary renal tumor and metastatic lesions within the same patient. Pretreatment 18F-FDG PET/CT provides whole-body information about tumor glucose metabolism, while radiomics can extract quantitative imaging features that may reflect tumor heterogeneity.
This is a single-center retrospective observational cohort study using existing clinical, pathological, treatment, follow-up, and pretreatment 18F-FDG PET/CT data. Eligible patients had pathologically confirmed metastatic renal cell carcinoma, underwent 18F-FDG PET/CT before starting first-line TKI plus ICI therapy, had at least one measurable lesion according to RECIST version 1.1, and had adequate treatment-response and follow-up information. The study did not assign treatment or alter routine clinical care.
Primary renal tumors and eligible metastatic lesions are segmented separately on pretreatment PET/CT images. Conventional metabolic parameters and radiomic features are extracted from each lesion. For patients with multiple metastatic lesions, lesion-level features are aggregated to generate patient-level variables. Primary-tumor, metastatic-lesion, and combined multi-lesion radiomics models are developed. Clinical and metabolic variables are also evaluated, and a combined prediction model is constructed. Patients are divided into training and internal validation cohorts for model development and evaluation.
The primary outcome is treatment response assessed approximately 12 weeks after treatment initiation according to RECIST version 1.1. Complete response and partial response are classified as responder status, while stable disease and progressive disease are classified as non-responder status. Progression-free survival is also evaluated to explore whether the prediction model is associated with longer-term treatment benefit.
The study population consists of adult patients with pathologically confirmed metastatic renal cell carcinoma who underwent pretreatment 18F-FDG PET/CT and received first-line axitinib plus pembrolizumab or toripalimab at the First Affiliated Hospital of Fujian Medical University. Eligible patients were identified retrospectively from institutional medical and imaging records. The study included patients with adequate clinical, pathological, imaging, treatment response, and follow-up data.
Exclusion Criteria:
Patients with pathologically confirmed metastatic renal cell carcinoma who underwent pretreatment 18F-FDG PET/CT and received first-line axitinib plus either pembrolizumab or toripalimab as part of routine clinical care. Clinical, pathological, imaging, treatment response, and follow-up data were retrospectively collected. Treatment was not assigned by the study.
Diagnostic Test: Pretreatment 18F-FDG PET/CT · Drug: Axitinib Plus Pembrolizumab or Toripalimab
Pretreatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography was performed before initiation of first-line systemic therapy. Primary renal tumors and eligible metastatic lesions were evaluated for conventional metabolic parameters and radiomic features.
Patients received first-line axitinib 5 mg orally twice daily combined with either pembrolizumab 200 mg intravenously every 3 weeks or toripalimab 240 mg intravenously every 3 weeks as part of routine clinical care. Treatment was not assigned by the observational study.
Treatment Response According to RECIST Version 1.1
Number and percentage of participants categorized as having complete response, partial response, stable disease, or progressive disease according to Response Evaluation Criteria in Solid Tumors version 1.1. Complete response and partial response are classified as responder status, while stable disease and progressive disease are classified as non-responder status.
Time frame: At 12 weeks after initiation of first-line TKI plus ICI therapy
Progression-Free Survival
Progression-free survival is defined as the time from initiation of first-line TKI plus ICI therapy to radiologically confirmed disease progression, death from any cause, or the last available follow-up, whichever occurs first. Participants without progression or death at the last follow-up are censored.
Time frame: From treatment initiation to radiologically confirmed disease progression, death, or last follow-up, assessed up to 24 months
Predictive Performance of the Multi-Lesion Radiomics Model
Discriminative performance of the pretreatment 18F-FDG PET/CT multi-lesion radiomics model for predicting responder status, evaluated using the area under the receiver operating characteristic curve in the training and internal validation cohorts.
Time frame: At 12 weeks after initiation of first-line TKI plus ICI therapy
Plan to share: No — Individual participant data will not be shared because the retrospective dataset contains sensitive clinical and imaging information and is subject to institutional privacy, data security, and ethics requirements.
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital of Fujian Medical University